To compare these results with those previously obtained using chemotherapy regimens, we also assessed the response rate and survival in a series of patients who were referred for metastatic MM or UM in the same centers before the approval of anti-CTLA-4 and anti-PD-1 mAbs and were treated with various chemotherapy regimens as first-line treatment. This evidence concerns the gene PDCD1 and Miyoshi myopathy.